Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 04, 2026 07:30 ET | Source: Biogen Inc.

Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

Designation is supported by an exploratory analysis from the Phase 1b study showing that some children with SMA previously treated with gene therapy who had suboptimal clinical status experienced...
June 04, 2026 01:00 ET | Source: Biogen Inc.

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at...
June 03, 2026 07:30 ET | Source: Biogen Inc.

Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses

Data presentations across multiple kidney diseases illustrate the breadth of Biogen’s nephrology portfolio with EMPAVELI® (pegcetacoplan) and felzartamab, an investigational anti-CD38 monoclonal...
June 01, 2026 01:30 ET | Source: Biogen Inc.; UCB

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

Publication adds to previously reported findings from Phase 3 PHOENYCS GO study, demonstrating statistically significant improvement in disease activity at Week 48 with dapirolizumab pegol plus...
May 21, 2026 18:00 ET | Source: Biogen Inc.

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpointsBased on data from the Phase 2b LUMA study, Biogen and Denali will discontinue...
May 14, 2026 08:35 ET | Source: Biogen Inc.

Biogen Completes Acquisition of Apellis Pharmaceuticals

CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a...
May 14, 2026 06:59 ET | Source: Biogen Inc.

Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease

Robust reductions in tau pathology were observed across all studied doses, with results generally consistent with those observed in the Phase 1b study1Pre-specified analyses of cognitive endpoints...
May 08, 2026 02:30 ET | Source: Biogen Inc.

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease

TOKYO and CAMBRIDGE, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review...
April 20, 2026 07:30 ET | Source: Biogen Inc.

Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region

With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one ownerAdvancing felzartamab – a CD38-directed...
March 31, 2026 06:59 ET | Source: Biogen Inc.

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE® FDA-approved...